Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma

NCT03971747 is registered in ClinicalTrials.gov with Shanghai AbelZeta Ltd. as lead sponsor.

NCT NCT03971747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
Lead sponsor
Shanghai AbelZeta Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 6, 2019
Completion date
April 30, 2021
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma